Page 64 - Read Online

Zhang et al. Neuroimmunol Neuroinflammation 2019;6:8 I http://dx.doi.org/10.20517/2347-8659.2019.06 Page 13 of 16

80. Okada K, Tsuji S, Tanaka K. Intermittent intravenous immunoglobulin successfully prevents relapses of neuromyelitis optica. Intern
Med 2007;46:1671-2.
81. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545-58
82. Montalban X, Gold R, Thompson AJ, Otero-Romero S, Amato MP, et al. ECTRIMS/EAN guideline on the pharmacological treatment
of people with multiple sclerosis. Mult Scler 2018;24:96-120.
83. Rae-Grant A. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report
of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. Neurology
2019;92:110-1.
84. Sahraian MA, Moghadasi AN, Azimi AR, Asgari N, et al. Diagnosis and management of Neuromyelitis Optica Spectrum Disorder
(NMOSD) in Iran: a consensus guideline and recommendations. Mult Scler Relat Disord 2017;18:144-51.
85. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, et al. EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur
J Neurol 2010;17:1019-32.
86. Trebst C, Berthele A, Jarius S, Kümpfel T, Schippling S, et al. Diagnosis and treatment of neuromyelitis optical consensus
recommendations of the Neuromyelitis Optica Study Group. Nervenarzt 2011;82:768-77.
87. The IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of
a multicenter, randomized, double-blind, placebo-controlled trial. Neurology 1993;43:655-61.
88. Paty DW, Li DK; UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group. Interferon beta-1b is effective in
relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial.
Neurology 1993;43:662-7.
89. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, Richert JR, et al. Intramuscular interferon beta-1a for disease progression in
relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39:285-94.
90. Pozzilli C, Bastianello S, Koudriavtseva T, Gasperini C, Bozzao A, et al. Magnetic resonance imaging changes with recombinant human
interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 1996;61:251-8.
91. Rudick RA, Goodkin DE, Jacobs LD, Cookfair DL, Herndon RM, et al. Impact of interferon beta-1a on neurologic disability in
relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Neurology 1997;49:358-63.
92. Simon JH, Jacobs LD, Campion M, Wende K, Simonian N, et al. Magnetic resonance studies of intramuscular interferon beta-1a for
relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group. Ann Neurol 1998;43:79-87.
93. Calabresi PA, Kieseier BC, Arnold DL, Balcer LJ, Boyko A, et al. Pegylated interferon beta-1a for relapsing remitting multiple sclerosis
(ADVANCE): a randomised, phase 3, double- blind study. Lancet Neurol 2014;13:657-65.
94. Polman CH, Dahlke F, Thompson AJ, Ghazi M, Kappos L, et al. Interferon beta-1b in secondary progressive multiple sclerosis-outline
of the clinical trial. Mult Scler 1995;1:S51-4.
95. Kuhle J, Hardmeier M, Disanto G, Gugleta K2, Ecsedi M, et al. A 10-year follow-up of the European multicenter trial of interferonβ-1b
in secondary-progressive multiple sclerosis. Mult Scler 2016;22:533-43.
96. Andersen O, Elovaara I, Färkkilä M, Hansen HJ, Mellgren SI, et al. Multicentre, randomised, double blind, placebo controlled, phase III
study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry
2004;75:706-10.
97. ITur C, Montalban X, Tintoré M, Nos C, Río J, et al. Interferonβ-1b for the treatment of primary progressive multiple sclerosis: five-
year clinical trial follow-up. Arch Neurol 2011;68:1421-7.
98. Montalban X, Sastre-Garriga J, Tintoré M, Brieva L, Aymerich FX, et al. A single-center, randomized, double-blind, placebo-controlled
study of interferon beta-1b on primary progressive and transitional multiple sclerosis. Mult Scler 2009;15:1195-205.
99. Hegen H, Auer M, Deisenhammer F. Pharmacokinetic considerations in the treatment of multiple sclerosis with interferon-β. Expert
Opin Drug Metab Toxicol 2015;11:1803-19.
100. Bailon P, Won CY. PEG-modified biopharmaceuticals. Expert Opin Drug Deliv 2009;6:1-16.
101. Furber KL, Van Agten M, Evans C, Haddadi A, Doucette JR, et al. Advances in the treatment of relapsing-remitting multiple sclerosis:
the role of pegylated interferonβ-1a. Degener Neurol Neuromuscul Dis 2017;7:47-60.
102. Lalive PH, Neuhaus O, Benkhoucha M, Burger D, Hohlfeld R. Glatiramer acetate in the treatment of multiple sclerosis: emerging
concepts regarding its mechanism of action. CNS Drugs 2011;25:401-14.
103. Aharoni R. The mechanism of action of glatiramer acetate in multiple sclerosis and beyond. Autoimmun Rev 2013;12:543-53.
104. Racke MK, Lovett-Racke AE, Karandikar NJ. The mechanism of action of glatiramer acetate treatment in multiple sclerosis. Neurology
2010;74:S25-30.
105. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing
remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebo-controlled trial.1995. Neurology 2001;57:S16-24.
106. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, et al. Extended use of glatiramer acetate (Copaxone) is well tolerated and
maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Copolymer 1 Multiple Sclerosis Study Group.
Neurology 1998;50:701-8.
107. Johnson KP, Brooks BR, Ford CC, Goodman A, Guarnaccia J, et al. Sustained clinical benefits of glatiramer acetate in relapsing
multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000;6:255-66.
108. Liu C, Blumhardt LD. Benefits of glatiramer acetate on disability in relapsing-remitting multiple sclerosis. An analysis by area under
disability/time curves. The Copolymer 1 Multiple Sclerosis Study Group. J Neurol Sci 2000;181:33-7.
109. Khan O, Rieckmann P, Boyko A, Selmaj K, Zivadinov R, et al. Three times weekly glatiramer acetate in relapsing remitting multiple
sclerosis. Ann Neurol 2013;73:705-13.
110. Wolinsky JS, Narayana PA, O’ Connor P, Coyle PK, Ford C, et al. Glatiramer acetate in primary progressive multiple sclerosis: results
of a multinational, multicenter, double-blind, placebo-controlled trial. Ann Neurol 2007;61:14-24.